HUMA logo

Humacyte, Inc.

HUMA
Healthcare|Biotechnology|US
$0.45
+0.05 (+13.32%)
Tangible Book / Share
$0.13
Cash / Share
$0.34
Financing Filings (last 12 months)
5
Shelf registrations / offering prospectuses — latest Jun 11, 2026 (424B5). Possible dilution.

Upcoming Data Readouts (1)

Jun 2027
Est. completion
P3End Stage Renal Disease (ESRD)
To Compare the Efficacy and Safety of the ATEV With AVF in Female Patients With End-Stage Renal Disease Requiring Hemodialysis
NCT05908084n=121

Recent Press Releases

Humacyte Innovative Research in Coronary Bypass and Vascular Regeneration to be Highlighted at American Heart Association Scientific Sessions 2026
Nov 3, 2026 · GlobeNewsWire
Humacyte To Announce 2026 Third Quarter Financial Results and Provide Business Update on November 10, 2026
Nov 2, 2026 · GlobeNewsWire
Humacyte Strengthens Intellectual Property Portfolio with Issuance of New U.S. Patent Covering Symvess and Other Bioengineered Tissues
Oct 28, 2026 · GlobeNewsWire
Humacyte at ASN Kidney Week: Phase 3 Trial Built for Women Shows ATEV Advantage Over Fistula, Getting Patients Off Catheters Months Sooner
Oct 23, 2026 · GlobeNewsWire
Humacyte Provides Commercial Update and Highlights Rapid Acceleration of Symvess Adoption by Hospitals
Oct 15, 2026 · GlobeNewsWire
Humacyte Expands Board Expertise with Appointment of Scott Coward and Paul Kuznik
Sep 28, 2026 · GlobeNewsWire
Humacyte to Present at the H.C. Wainwright 28th Annual Global Investment Conference
Sep 10, 2026 · GlobeNewsWire
Humacyte Announces FDA Authorization Extending Symvess Shelf Life to 36 Months
Sep 9, 2026 · GlobeNewsWire
Humacyte Investigation Continued: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of Humacyte, Inc. - HUMA
Sep 4, 2026 · Business Wire
Humacyte Confirms Plans for ATEV Supplemental BLA Filing for Dialysis Access Following FDA Discussions
Aug 24, 2026 · GlobeNewsWire

SEC Filings (67)

Last two years from EDGAR. Insider Form 4s are on the Ownership tab.

FiledFormWhat it isLinks
Sep 28, 20268-KMaterial eventDocumentIndex
Aug 25, 202625-NSEDocumentIndex
Aug 18, 2026SC 13D/AActivist / 5%+ stakeDocumentIndex
Aug 12, 202610-QQuarterly reportDocumentIndex
Aug 12, 20268-KMaterial eventDocumentIndex
Jul 31, 20268-KMaterial eventDocumentIndex
Jul 28, 2026SC 13G/APassive 5%+ stakeDocumentIndex
Jul 13, 2026SC 13D/AActivist / 5%+ stakeDocumentIndex
Jun 22, 2026SC 13GPassive 5%+ stakeDocumentIndex
Jun 15, 2026SC 13D/AActivist / 5%+ stakeDocumentIndex
Jun 11, 20268-KMaterial eventDocumentIndex
Jun 11, 2026424B5Offering prospectusDocumentIndex
Jun 10, 2026424B5Offering prospectusDocumentIndex
Jun 10, 20268-KMaterial eventDocumentIndex
Jun 9, 20268-KMaterial eventDocumentIndex
Jun 5, 20268-KMaterial eventDocumentIndex
May 14, 2026S-8Employee stock planDocumentIndex
May 13, 202610-QQuarterly reportDocumentIndex
May 8, 20268-KMaterial eventDocumentIndex
Apr 28, 2026DEF 14AProxy / shareholder voteDocumentIndex
Apr 27, 2026SC 13D/AActivist / 5%+ stakeDocumentIndex
Apr 24, 20268-KMaterial eventDocumentIndex
Apr 17, 2026PRE 14AProxy / shareholder voteDocumentIndex
Mar 27, 202610-KAnnual reportDocumentIndex
Mar 24, 2026SC 13D/AActivist / 5%+ stakeDocumentIndex
Mar 19, 20268-KMaterial eventDocumentIndex
Mar 19, 2026424B3Offering prospectusDocumentIndex
Mar 19, 20268-KMaterial eventDocumentIndex
Jan 9, 2026SC 13D/AActivist / 5%+ stakeDocumentIndex
Dec 16, 20258-KMaterial eventDocumentIndex
Dec 16, 2025424B5Offering prospectusDocumentIndex
Dec 15, 20258-KMaterial eventDocumentIndex
Dec 15, 20258-KMaterial eventDocumentIndex
Dec 15, 2025424B3Offering prospectusDocumentIndex
Nov 26, 20258-KMaterial eventDocumentIndex
Nov 12, 202510-QQuarterly reportDocumentIndex
Nov 12, 20258-KMaterial eventDocumentIndex
Oct 16, 2025SC 13D/AActivist / 5%+ stakeDocumentIndex
Oct 7, 20258-KMaterial eventDocumentIndex
Oct 7, 2025424B3Offering prospectusDocumentIndex